News Articles

Trading Room

100+ Years of combined Market Experience!

Brexit Is A Reminder That Volatility Is Here For The Long Run

The latest events surrounding Brexit are a reminder that volatility in markets will continue as the UK is now set up for a do-over vote on the divorce from the EU. Volatility in the British pound currency will continue.
By Andy Hecht

Reviewing Indicators – Citi Economic Surprise Index, Global PMIs, ECRI

PeriodicaIly I add an installment to my series on economic indicators. In these posts I combine important selection principles with examples of some of my conclusions.
By Jeff Miller

Business Cycle Update

In this note we look at the business cycle and analyze the major coincident data points of the US economy, and also ask: Can the economy slip into recession even if housing data remains "strong?"
By Eric Basmajian

Copper Waits For News

The falling dollar, declining stockpiles on the LME and COMEX, and optimism over progress in negotiations could make both copper and FCX an attractive buy at their current levels.
By Andy Hecht

Where Is The Biotech Sector Headed Next After The Recent Plunge?

With the recent sharp plunge in the biotechnology sector, which exceeded the pullback in the broad U.S. equity markets, I am getting investor questions about my outlook for the biotech sector over the next few months and long-term. In this article, I will provide my near-term and long-term outlook for the biotech sector as well as mention some top acquisition candidates over the next 12 months.
By Bhavneesh Sharma

The Dollar And Gold

The dollar and gold have an inverse history. A strong dollar had tended to weigh on the price of gold while a weaker dollar had been supportive of the price of the precious metal. These days, however, both the dollar and gold are exhibiting price strength.
By Andy Hecht

Setting the Bar Too High

The much-awaited trade news is about to be released. I expect almost everyone to become a critic.
By Jeff Miller

Who Benefits from Cheap Oil? India, for Starters.

I have a long-term bullish outlook on India as part of a diversified portfolio, but there is one main thing holding me back from being quite as bullish as I am on, say, Russia. And that is India’s heavy reliance on oil imports, which damages its current account and continually weakens its currency.
By Lyn Alden Schwartzer

Why This Slowdown Carries Elevated Risks

As the fourth quarter gets off to a rocky start, the consensus narrative is fully aware of the ongoing slowdown in global manufacturing that began over 20 months ago and is warming to the idea that the manufacturing malaise has spread to the services sector.
By Eric Basmajian

Inflation Cycle Downturn

The headline metrics from the Producer Price Index report, released this morning by the Bureau of Labor Statistics, continued to highlight a deceleration in the rate of inflation while the more cyclical sub-components suggest downside pressure has not yet eased.
By Eric Basmajian

An Analysis of Karuna Therapeutics' Upcoming Phase 2 Schizophrenia Data Readout

Karuna Therapeutics (KRTX), which is trading below its recent IPO price, has a key price-moving data release later this year: Phase 2 data from a randomized, placebo-controlled trial of KarXT in treating patients with schizophrenia and acute exacerbation of psychosis.
By Bhavneesh Sharma

Gold Royalty Stocks Update (Yep, Still Buying)

I added a combination of gold, silver, gold miners, and gold royalty companies to my model portfolio in my November 2018 newsletter issue (with an overweight emphasis on the royalties), and have been buying ever since, through dips and peaks.
By Lyn Alden Schwartzer

Political Tail Wagging

Art Cashin, the best source for opinion on the NYSE floor, opined yesterday that 200-300 points of the DJIA decline was because of Sen. Sanders' health issues. Apparently the logic goes that if Sanders were out of the race, Warren chances would improve. She is the candidate, rightly or wrongly, most feared by Wall Street.
By Jeff Miller

Invest In Disruption And Sustainability

"Buy the disruptors, sell the disrupted." This was the message from Stanley Druckenmiller earlier this year at The Economic Club of New York. As the economy changes, I would reiterate what I have been saying since FATrader launched earlier this year, focus on changes in tech, healthcare and the energy systems, that is where the most disruption is.
By Kirk Spano

Confirmation Biases - Market Analysis on Oct 2nd, 2019

Everyone who has been "warning" (including those doing so for many years) are seizing on some one-month data points as confirmation. It is confirmation bias, because the same sources ignore the good economic news.
By Jeff Miller

Eyeing Intercept Pharmaceuticals On New Drug Application to Treat Fibrosis Due to NASH

Intercept Pharmaceuticals (NASDA: ICPT) submitted a New Drug Application (NDA) last week for its obeticholic acid (OCA) treatment for patients with fibrosis due to nonalcoholic steatohepatitis (NASH). The company has requested a Priority Review from FDA which would reduce the anticipated review period to six months.
By Bhavneesh Sharma

Bitcoin Bottoming In Process

The bottom process in Bitcoin is still, well, in process. We are seeing immense chop here and no impulsive structures off our lows, so we must assume the bottom is not yet in.
By Ryan Wilday

Issues On The Horizon In The Final Quarter of 2019 In Commodities

The many issues facing markets in Q4 are likely to present more than a handful of trading opportunities over the coming months. With the natural gas market moving into its peak season of demand in November and the price at the $2.40 per MMBtu level, the energy commodity is one of my favorite plays.
By Andy Hecht

The CEF Contrarian Indicator

In addition to my primary focus on measuring value in various asset classes, regions, and stocks, an additional and unusual place I like to look for signs of exuberance is in the world of Closed End Funds, or “CEFs”.
By Lyn Alden Schwartzer

Bitcoin / GBTC Update

This is a scalpers market right now, until this correction is over.
By Ryan Wilday

This Stock Grows by 12% and Yields 6%, But You Won't Like It

Sberbank is the largest bank in Russia, and one of my top long-term aggressive stock ideas.
By Lyn Alden Schwartzer

The Industrial Slowdown Continues Into September

Industrial activity in the United States continued on a downward path through the end of August with industrial production growth falling to a 31-month low.
By Eric Basmajian

Aimmune's Palforzia: The First Potential FDA Approved Oral Immunotherapy For Peanut Allergy

The FDA's Adcom panel voted on Friday to approve the use of Aimmune Therapeutics (AIMT)'s peanut desensitization therapy in children and teens with peanut allergy.
By Bhavneesh Sharma

This Week's Data: Implications for the Fed

This has been an interesting week for economic data. The general implication is hawkish for Fed policy and supportive of a shift in overall asset allocation. Let’s take a closer look.
By Jeff Miller

A Look at Some Global Cash Cows

The ICOW ETF is probably the most interesting in my view, because the financial sector has been my biggest concern with the ex-US developed world for the past few years. This vehicle provides a potential way to gain that exposure for those that want it without the bank and insurance companies in those regions.
By Lyn Alden Schwartzer

Sign Up Now - Free 15-Day Trial! Go! Fatty!